New Lipitor ad features testimonial from heart attack survivor

Share this article:
Lipitor ad
Lipitor ad

Pfizer will resume DTC advertising for its blockbuster statin drug, Lipitor (atorvastatin calcium)--but this time the pitchman isn't so famous. Pfizer took heat from federal regulators and the media when it used artificial heart inventor Robert Jarvik (not a physician) to promote Lipitor for its previous Lipitor DTC campaign. This time around Pfizer is using a “real person” who suffered a heart attack.

In the new print and television advertisements, which were set to appear the first week of September, the patient tells viewers and readers: “Talk about a wake-up call. I had a heart attack at 57. I should have been doing more for my high cholesterol. I learned the hard way.” The copy goes on to say: “Now I trust my heart to Lipitor. Talk to your doctor about your risk and about Lipitor.” The main theme of the new ad campaign is “a Lipitor heart-to-heart.”

Separately, Pfizer unveiled data from a five-year Treating to New Targets (TNT) study presented at the 2008 European Society of Cardiology Congress, that revealed in patients with established heart disease, Lipitor 80 mg not only significantly reduced the relative risk of suffering a first cardiovascular event by 19% compared to Lipitor 10 mg, but also provided a sustained reduction in the risk of a subsequent second, third, fourth and fifth cardiovascular event.

Lipitor, which had sales of $12.7 billion in 2007, will be facing stiff competition from generic versions of the drug when it looses its copyright protection in 2011.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...